Dragon Pharma, Europe
SLU-PP-332
Oral · 500 mcg/tab · 100 tabs
$110.00
Compound ID
SLU-PP-332
Dosage
500–1000 mcg/day
Concentration
500 mcg/tablet
Form
100 tabs × 500 mcg
Half-life
Approximately 6–8 hours
Shipping
Not available in this combination
Product overview
Dragon Pharma SLU-PP-332 500mcg — Exercise Mimetic Metabolic Modulator for Advanced Body Recomposition
Dragon Pharma SLU-PP-332 500mcg delivers a precise dose of an innovative metabolic modulator designed to activate energy expenditure pathways without stimulant-driven side effects. As an ERR receptor agonist, this oral compound pharmacologically mimics the metabolic adaptations of prolonged aerobic training, shifting fuel preference toward fatty acid oxidation. Each sachet contains one hundred 500mcg tablets manufactured under certified standards, providing a novel tool for athletes seeking sustained fat loss and endurance enhancement without hormonal suppression.
What is Dragon Pharma SLU-PP-332 500mcg?
This oral metabolic agent contains SLU-PP-332, a synthetic compound that targets estrogen-related receptors alpha, beta, and gamma. Originally developed from academic metabolic research, it functions as an exercise mimetic by activating the same transcriptional pathways stimulated by endurance training.
Unlike sympathomimetic fat burners that elevate heart rate and blood pressure, this compound works at the nuclear receptor level to increase mitochondrial density and oxidative capacity. The 500mcg tablet strength allows for flexible split dosing to accommodate its moderate half-life.
Key Benefits / Effects
- Enhanced Fat Oxidation: This metabolic modulator shifts cellular fuel preference toward fatty acids, increasing resting energy expenditure and promoting efficient adipose mobilization without stimulant side effects.
- Substantial Endurance Gains: By upregulating mitochondrial biogenesis and oxidative metabolism in skeletal muscle, it supports dramatic improvements in stamina and aerobic training capacity.
- Lean Tissue Preservation: The compound helps maintain muscle mass during caloric restriction by improving metabolic efficiency and nutrient partitioning favoring protein sparing.
- Non-Stimulant Energy: Users report increased vitality and alertness through enhanced cellular ATP production rather than catecholamine release, eliminating jitters, anxiety, or post-dose crashes.
- Metabolic Health Support: Early investigations suggest improvements in insulin sensitivity and lipid parameters, contributing to favorable overall metabolic profile during intensive dieting.
- No Hormonal Suppression: Because it targets metabolic receptors rather than the endocrine axis, it does not interfere with natural testosterone, thyroid, or growth hormone output.
How Dragon Pharma SLU-PP-332 500mcg Works
SLU-PP-332 binds to and activates estrogen-related receptors in skeletal muscle, cardiac tissue, and the central nervous system. These nuclear receptors serve as master regulators of genes controlling oxidative metabolism, mitochondrial function, and energy homeostasis.
Activation upregulates PGC-1 alpha and other transcriptional coactivators that drive mitochondrial proliferation and fatty acid oxidation enzymes. The result is a cellular environment resembling that of an endurance-trained athlete, where muscles preferentially burn lipids for fuel and exhibit greater resistance to fatigue.
This mechanism operates independently of beta-adrenergic or thyroid pathways, explaining the absence of cardiovascular stimulation or endocrine disruption.
Usage Information
This metabolic agent is supplied in 500mcg oral tablets. Due to a half-life of approximately six to eight hours, the daily dose is typically split into two administrations.
New users should begin with 250mcg in the morning and 250mcg in the early afternoon to assess tolerance. After one to two weeks, many increase to 500mcg twice daily for more pronounced metabolic and endurance effects. Advanced protocols may utilize 500mcg twice daily consistently throughout an eight-week cycle.
Because it does not suppress endogenous hormone production, no post-cycle therapy is required. Discontinuation can occur without tapering, though maintaining adequate protein intake and micronutrient density supports the metabolic adaptations achieved during the protocol.
Quality & Manufacturing
Each sachet is produced in certified facilities with rigorous content uniformity testing. The 500mcg dose requires precision because the compound operates at the microgram level to produce meaningful receptor activation.
Pharmaceutical-grade tablet pressing ensures consistent dissolution and predictable pharmacokinetics. For a novel metabolic agent, verified manufacturing eliminates the variability and contamination risks associated with unverified sources.
Possible Side Effects / Safety Information
- Transient Fatigue: Some users report mild tiredness during the initial adaptation period as cellular metabolism shifts toward oxidative pathways. Adequate rest and hydration typically resolve this within the first week.
- Gastrointestinal Sensitivity: Nausea or mild stomach discomfort may occur in sensitive individuals, particularly at higher doses or when taken without food.
- Unknown Long-Term Profile: As a newer compound, extensive human longitudinal data is limited. Users should approach protocols conservatively and monitor overall health markers throughout the cycle.
- Not a Substitute for Training: While it mimics exercise metabolic pathways, it does not replace the mechanical, neurological, or structural adaptations produced by actual resistance and cardiovascular work.
Why Choose Dragon Pharma SLU-PP-332 500mcg?
The exercise mimetic mechanism offers a fundamentally different approach to body recomposition compared to stimulant or hormonal fat burners. By targeting ERR receptors, it enhances endurance and fat oxidation without elevating heart rate, suppressing testosterone, or requiring post-cycle recovery.
For athletes who have exhausted conventional thermogenic options or wish to avoid sympathomimetic side effects, this metabolic modulator provides a clean, non-suppressive alternative. Verified tablet potency and certified manufacturing ensure each dose delivers the expected receptor activation for consistent results.
Product FAQ
Questions, answered
An exercise mimetic is a compound that activates the same cellular pathways as physical training. This product binds to estrogen-related receptors, upregulating genes that control mitochondrial function and fatty acid oxidation, effectively telling muscle cells to behave as if they are endurance-conditioned.
Traditional thermogenics like clenbuterol or ephedrine activate the sympathetic nervous system, raising heart rate and blood pressure. This compound works at the nuclear receptor level to increase metabolic efficiency without catecholamine release, producing no jitters, crashes, or cardiovascular strain.
No. It does not interact with the hypothalamic-pituitary-testicular axis, thyroid feedback loops, or growth hormone secretion. No post-cycle therapy or tapering is required upon discontinuation.
Many users notice increased training stamina and reduced fatigue between sets within 2–3 weeks. Fat oxidation effects typically become measurable after 3–4 weeks of consistent split dosing.
Yes. It pairs well with growth hormone secretagogues, thyroid support, or non-stimulant metabolic enhancers. Avoid combining with multiple stimulants unless you have extensive experience managing cardiovascular load.
It is best suited for experienced athletes who understand metabolic enhancement and can accurately assess changes in training capacity and body composition. Beginners should first establish solid nutritional and training foundations.
The 6–8 hour half-life means concentrations decline substantially within a single day. Split dosing maintains stable receptor activation throughout waking hours, optimizing both fat oxidation and endurance support.
No. Early data and user reports indicate no association with subcutaneous fluid accumulation. The mechanism operates through intracellular metabolic shifts rather than hormonal water retention pathways.
Yes. Because it does not affect sex hormone pathways, it is suitable for female athletes seeking endurance and body recomposition benefits without androgenic or virilization risks.
A moderate caloric deficit with high protein intake maximizes the muscle-preserving and fat-oxidizing effects. Diets rich in healthy fats may synergize with the compound's preference for fatty acid fuel sources.
Both classes enhance endurance and fat oxidation, but through different receptor families. PPAR delta agonists like cardarine primarily affect lipid metabolism genes, while ERR agonists more broadly coordinate mitochondrial biogenesis and oxidative capacity across multiple tissue types.
As a novel agent dosed in micrograms, even minor manufacturing inconsistencies can significantly alter receptor activation. Verified 500mcg potency ensures users receive the precise pharmacological stimulus required for predictable metabolic enhancement without underdosing or unexpected potency spikes.
